Source Innovation And China’s Crouching Tiger Reality In 2022
Still Attractive Despite Hurdles?
Executive Summary
While China’s increasingly inward-looking macro economic policies and other regulatory hurdles are likely to impact smaller players, positive biopharma policy moves in competing hub contenders including Shanghai and the Greater Bay Area also offer attractive opportunities.